Review
Biochemistry & Molecular Biology
Misung Park, Dohee Kim, Sunghyub Ko, Ayoung Kim, Kyumin Mo, Hyunho Yoon
Summary: Breast cancer is the most common malignancy in women worldwide, and metastasis is the leading cause of high mortality. Currently, breast cancer is often discovered or diagnosed after metastasis has occurred, resulting in poor prognosis. Understanding the mechanisms and nature of breast cancer metastasis can facilitate the development of targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Xiaobin Zeng, Chengxiao Liu, Jie Yao, Haoqiang Wan, Guoqing Wan, Yingpeng Li, Nianhong Chen
Summary: Both hereditary and sporadic breast cancer may stem from a subcomponent of stem cells with dysregulated self-renewal pathways. Cancer stem cells play a crucial role in treatment resistance and tumor initiation, highlighting the importance of therapeutic strategies targeting these cells.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Medicine, Research & Experimental
Sara S. Bashraheel, Hadeel Kheraldine, Sarah Khalaf, Ala-Eddin Al Moustafa
Summary: Due to the strong association between diabetes and cancer incidents, several anti-diabetic drugs, including metformin, have been examined for their anticancer activity. Metformin exhibits anticancer activity by impacting different molecular pathways and indirectly inhibiting IGF-1R signaling in breast malignancy. Breast cancer, especially the HER2-positive subtype, is highly aggressive with a high rate of lymph node metastasis. This review summarizes the association between diabetes and human cancer, focusing on metformin's anticancer activity and combination therapy strategies in HER2-positive breast cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Oncology
Kit Yee Wong, Alvin Ho-Kwan Cheung, Bonan Chen, Wai Nok Chan, Jun Yu, Kwok Wai Lo, Wei Kang, Ka Fai To
Summary: Lung cancer is a common and deadly disease, with the tumor microenvironment playing a crucial role. Cancer-associated fibroblasts (CAFs) have gained attention in the study of nonsmall cell lung carcinoma (NSCLC), as their heterogeneity and functions are closely associated with tumor development.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Oncology
Liqin Yao, Junfeng Chen, Wenxue Ma
Summary: This review article focuses on the expression patterns, clinical implications, and therapeutic advancements of TROP2 in breast cancer, highlighting the importance of personalized treatments and the potential to transform breast cancer care.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Shefali Thakur, Syed Haider, Rachael Natrajan
Summary: Tumour heterogeneity is a common feature in many cancers, leading to disease progression and therapy resistance. This review focuses on recent advances in understanding the interaction between tumour cells and their microenvironment in breast cancer, using single cell sequencing and digital spatial profiling technologies. The utility of lineage tracing methodologies in pre-clinical models of breast cancer and their role in identifying therapeutic vulnerabilities and biomarkers of breast cancer progression are also discussed.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Umar Mehraj, Umar Mushtaq, Manzoor A. Mir, Afnan Saleem, Muzafar A. Macha, Mohammad Nadeem Lone, Abid Hamid, Mohammed A. Zargar, Syed Mudasir Ahmad, Nissar Ahmad Wani
Summary: Tumor heterogeneity is a critical issue in the treatment of triple-negative breast cancer (TNBC), a highly diverse and aggressive subtype of cancer. Chemokines play a significant role in regulating TNBC heterogeneity. Understanding the chemokine networks involved in TNBC can lead to the development of effective therapeutic strategies.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Medicine, General & Internal
Caterina Fumagalli, Massimo Barberis
Summary: Breast tumor heterogeneity presents a major challenge in the clinical management of breast cancer patients, with each breast cancer potentially having different prognosis and benefiting from specific therapy. The dynamic nature of breast cancer, evolving during tumor progression and metastatization, poses challenges for personalized medicine approaches. Evaluation of biopsies from metastatic sites is crucial for determining the most effective therapeutic strategy for recurrent disease, with radiogenomics and liquid biopsy being valuable non-invasive tools for assessing breast cancer heterogeneity.
Review
Oncology
Yelyzaveta Shlyakhtina, Katherine L. Moran, Maximiliano M. Portal
Summary: The manuscript summarizes the complex and dynamic nature of adaptation mechanisms and evolutionary processes during cancer initiation, development, and progression. It discusses the importance of non-genetic mechanisms in cancer evolution and the potential for predicting and guiding the evolutionary path of cancer populations towards drug-sensitive phenotypes. Despite the unknown mechanisms underlying evolutionary processes within tumors, most tumors display features compatible with diverse evolutionary paths. The ultimate goal is to understand the genetic and non-genetic networks underlying tumor evolution to develop more effective anti-cancer approaches.
Review
Cell Biology
Kevin M. Turner, Syn Kok Yeo, Tammy M. Holm, Elizabeth Shaughnessy, Jun-Lin Guan
Summary: Breast cancer exemplifies how molecular characterization influences therapeutic decisions. The compartmentalization of breast cancer into diverse subtypes is well-documented, but intratumoral heterogeneity, driven by both intrinsic and extrinsic factors, complicates this model. Evidence suggests that intratumoral molecular subtypes are dynamic and interconversion between subtypes contributes to tumor progression, metastases, and treatment resistance. Therapeutic strategies need to address this heterogeneity to improve treatment outcomes.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2021)
Review
Immunology
Jianan Zhao, Shicheng Guo, Steven J. Schrodi, Dongyi He
Summary: Rheumatoid arthritis displays significant clinical heterogeneity and personalized responsiveness to standard treatments, with understanding individual variation in cellular and molecular mechanisms being crucial for improving patient outcomes. Pathological heterogeneity derived from genetic, molecular, and cellular factors influences precision medicine and personalized treatment approaches for rheumatoid arthritis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Mingxi Lin, Ting Luo, Yizi Jin, Xiaorong Zhong, Dan Zheng, Cheng Zeng, Qing Guo, Jiong Wu, Zhi-Ming Shao, Xichun Hu, Wentao Yang, Jian Zhang
Summary: Intrapatient primary-to-metastatic and intermetastatic HER2 heterogeneity was observed in this large-scale cohort study. The prediction tool developed by the authors might help clinicians screen out patients with primary HER2-negative tumors who have a high probability of HER2 status conversion and recommend them with for re-biopsy, thus helping to screen out candidate patients for trastuzumab deruxtecan treatment.
Article
Oncology
Ke Jiang, Mengting Dong, Chunyang Li, Jiayu Sheng
Summary: This study systematically characterized the tumor heterogeneity of TNBC using single-cell RNA sequencing, revealing the existence of multiple immune cell types and their associations with clinical outcomes in TNBC tissues, particularly highlighting the significance of M2 macrophages and neutrophils.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Yue Jiang, Juliang Zhang
Summary: Breast cancer is a leading cause of cancer-related deaths worldwide, and immunotherapy is considered a major therapeutic strategy for the disease. The cGAS-STING pathway plays a crucial role in breast cancer immunity and shows promising therapeutic effects. This review discusses the latest research findings on the role and activation of the cGAS-STING pathway in breast cancer.
Review
Oncology
Hanne Lefrere, Liesbeth Lenaerts, Virginia F. Borges, Pepper Schedin, Patrick Neven, Frederic Amant
Summary: Breast cancers diagnosed in young women within 5 to 10 years postpartum are associated with higher risks of metastasis and death compared to those diagnosed in young women during or outside of pregnancy. The (immuno)biology of postpartum breast cancer is not well understood, leading to uncertainties in effective targeting for improved survival. Treatments and the impact of lactation on breast cancer outcomes after diagnosis are also areas that require further research.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)